Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.540
-0.110 (-4.15%)
At close: Jun 13, 2025, 4:00 PM
2.481
-0.059 (-2.33%)
After-hours: Jun 13, 2025, 7:51 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $545.24 million as of June 13, 2025. Its market cap has decreased by -10.29% in one year.
Market Cap
545.24M
Enterprise Value
490.28M
1-Year Change
-10.29%
Ranking
Category
Stock Price
$2.54
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $545.24M, a decrease of -21.03%. That is a compound annual growth rate of -4.88%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 12, 2025 | 568.85M | 60.44% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 728.99B |
| Johnson & Johnson | 376.94B |
| Novo Nordisk | 357.59B |
| AbbVie | 339.89B |
| UnitedHealth Group | 288.92B |
| Abbott Laboratories | 237.40B |
| Novartis AG | 236.22B |
| AstraZeneca | 232.37B |